Core Viewpoint - The approval of the active pharmaceutical ingredient (API) for Minaprine Hydrochloride by the National Medical Products Administration indicates that the product meets national drug approval technical standards, allowing for production and sales in the domestic market, which will enhance the company's market competitiveness and positively impact future development [1] Group 1 - The company’s wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received the approval notice for the API Minaprine Hydrochloride [1] - Minaprine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre for the treatment of major depressive disorder [1] - The approval will help the company advance the integration of its product supply chain, optimize resource allocation, and improve its industry layout [1]

Core Viewpoint - The approval of the active pharmaceutical ingredient (API) for Minaprine Hydrochloride by the National Medical Products Administration (NMPA) signifies a positive development for the company, enhancing its market competitiveness and resource allocation [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received the approval notice for the listing application of Minaprine Hydrochloride [1] - Minaprine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre, intended for the treatment of major depressive disorder [1] - The approval indicates that the API meets national pharmaceutical approval technical standards, allowing for production and sales in the domestic market [1] Group 2: Strategic Implications - The approval will assist the company in advancing the industrial chain integration of related products, optimizing resource allocation and industrial layout [1] - This development is expected to enhance the company's product market competitiveness and positively impact future growth [1] - The matter is not anticipated to have a significant impact on the company's current operating performance [1]

Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient, Minaprine Hydrochloride [1] Group 1 - The approved drug, Minaprine Hydrochloride, is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre, intended for the treatment of major depressive disorder [1]

Core Viewpoint - The approval of the active pharmaceutical ingredient, Mianaprine Hydrochloride, by the National Medical Products Administration is a significant milestone for the company, enhancing its integrated supply chain capabilities while facing sales uncertainties due to various factors [1] Group 1: Regulatory Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Jiangsu Weichida, received the approval notice for the listing application of Mianaprine Hydrochloride [1] - The approval is crucial for the treatment of severe depression, with a global consumption of 3,639.95 kg in 2023 [1] Group 2: Research and Development - The application for the active pharmaceutical ingredient was submitted in October 2024 and passed the review in February 2026 [1] - The total R&D investment for this project amounted to approximately 7.1823 million yuan [1] Group 3: Market Implications - The approval supports the company's efforts to advance its integrated supply chain [1] - However, sales of the product may be influenced by multiple factors, leading to uncertainties in market performance [1]